SCHEMBL4099002

SCHEMBL4099002

CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCC(N4CCOCC4)CC3)ccc2OC)ncc1Br

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 4/20 0.79
ALK Q9UM73 11/20 0.71
IGF1R P08069 5/20 0.71
PLK4 O00444 2/20 0.71
CHEK1 O14757 2/20 0.71
AURKA O14965 2/20 0.71
DCLK1 O15075 2/20 0.71
PDPK1 O15530 2/20 0.71
DAPK3 O43293 2/20 0.71
JAK2 O60674 2/20 0.71
ROCK2 O75116 2/20 0.71
PRKD3 O94806 2/20 0.71
MAP4K4 O95819 2/20 0.71
PAK4 O96013 2/20 0.71
CHEK2 O96017 2/20 0.71
EGFR P00533 2/20 0.71
ERBB2 P04626 2/20 0.71
NTRK1 P04629 2/20 0.71
LCK P06239 2/20 0.71
FYN P06241 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL380944 0.93 ULK1 (0.88) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL4103561 0.92 ULK1 (0.67) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL4094604 0.92 ALK (0.72) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL4096523 0.88 ALK (0.80) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL10207519 0.88 ULK1 (0.76) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL375608 0.88 ULK1 (1.00) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL29900883 0.88 ULK1 (1.00) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL12781002 0.88 ULK1 (0.77) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL4095269 0.87 ALK (0.81) ULK1ALKIGF1RPLK4CHEK1
SCHEMBL4100115 0.86 ALK (0.63) ULK1ALKIGF1RPLK4CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US claimed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP claimed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO claimed
US-20090131436-A1 Pyrimidine Derivatives NOVARTIS AG (CH) 2009-05-21 US disclosed
EP-1784392-A2 PYRIMIDINE DERIVATIVES Novartis AG (CH) 2007-05-16 EP disclosed
WO-2006021454-A2 PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131436-A1 Pyrimidine Derivatives DPYD, TYMP, TYMS ULK1 1714/4885ALK 2060/4885IGF1R 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.